E-news: Low dose pegvisomant in combination therapy for acromegaly

A recent study by Van Der Lely and colleagues examined 92 patients with acromegaly inadequately controlled despite somatostatin or pegvisamont monotherapy.

The addition of low dose pegvisomant (60mg weekly) to standard somatostatin analogue therapy, had an efficacy equal to that of double the dose pegvisomant monotherapy.

This has major cost implications as well as being attractive clinically, as the beneficial effect on tumour size achieved by SSA therapy, is maintained, with the additional benefit of biochemical control achieved by pegvisomant.